Israeli company developing medical cannabis spray to treat skin conditions
The innovative topical spray is expected to effectively treat atopic dermatitis, psoriasis, pain and lesions.
By Idan Zonshine, Jerusalem Post, January 19, 2021
A CanBreed researcher takes a sample from a cannabis plant. (photo credit: CANBREED)
Israeli medical cannabis company Cannassure announced on Tuesday that they will be developing a topical cannabis spray to treat a variety of inflammatory skin conditions, along with Swedish Pharmaceutical company Lipidor, which specializes in dermatology.
The
companies signed a development agreement together after successfully
completing the feasibility stage in the process of developing an
over-the-counter (OTC) topical spray for the treatment of inflammatory skin conditions such as atopic dermatitis, psoriasis, pain and lesions.
In addition to the development deal, Cannassure will now have the
exclusive right to use Lipidor's innovative AKVANO® topical spray
technology.
According
to Cannassure's estimates, the combined treatment market for all of
these chronic illnesses and symptoms could be worth over $50 billion by
2027.
The
feasibility study looked at different models to see whether Cannassure's
cannabinoids were compatible with Lipidor's topical drug delivery spray
technology.
Cannassure
said that it has proven that the cannabinoids can be well combined into
the AKVANO system, into a homogeneous, uniform and stable formulation.
Cannassure
CEO Ran Amir stated that the company looked forward to the joint
development process, saying that "The AKVANO non-touch application
paired with an excellent uptake of active substance in different skin
layers opens up the door for new high-potential treatments with great
patient benefits."
After the OTC topical spray, Amir said that Cannassure plans to
expand to also developing prescription-based pharmaceutical products,
adding that they have seen "significant interest from distributors."
Ola
Holmlund, CEO of Lipidor AB, was "delighted" about the licensing
agreement and emphasized the importance of the feasibility study's
results.
“This is
an important milestone and an external validation of our unique
formulation platform, showing that cannabinoids can also be well
incorporated into AKVANO," Holmlund said.
"Cannassure’s
advanced production facility, development resources and distribution
relationships for medical cannabis are of a high standard," Holmlund
said, adding that "We have great faith in Cannassure as well as high
expectations on the partnership with the aim to commercialize the new
drugs as soon as possible.”
Please recommend this page & follow the Sputniks Orbit
No comments:
Post a Comment